Our business

Gilbert Technologies operates in the pulmonary pharmaceutical delivery market.
We develop and commercialize unique and disruptive innovative medical devices for inhalation of medicines by electrohydrodynamic atomization (EHDA).

Pulmonary drug delivery market

A route of administration in pharmacology is the pathway by which a medicine is brought into contact with the body.
A substance must be transported from the site of entry to the part of the body where its action is desired. Using the body’s transport mechanisms for this purpose, however, is not trivial. The pharmacokinetic properties of a medicine (that is, those related to processes of uptake, distribution, action and elimination) are critically influenced by the route of administration. There are various routes of administration: intradermal, intrathecal, intramuscularly, intranasal, intravenously, oral, rectally, subcutaneously, sublingually, topically or vaginally. Some medications can be given by only one route because absorption or maximum effectiveness occurs by that route only or because the specific substance is toxic or damaging when given by another route.
Gilbert Technologies focuses inexplicitly on pulmonary administration.

The advantages for inhalation or pulmonary administration are:

  • Preferred route of administration for lung diseases
  • Fastest method (7–10 seconds for the drug to reach the brain) for acute treatment
  • User can titrate (regulate the dosage of the pharmaceutical)
  • Potential for lower dosage and lower systemic side-effects.

Read more about: pulmonary administration route

Clinical need

A clinical need for new technology exists because of limitations of existing technology. Many commercially available inhalers such as DPI’s and MDI’s all come with their specific disadvantages. A relatively low percentage of medicine particles effectively reaches the right regions of the lungs (a mere 10-20% for most inhalers, the remaining 80-90% is lost in the oropharynx, the inhaler itself, exhaled breath and the environment, which puts a real burden on treatment effectiveness). Furthermore, there is a growing interest in using the pulmonary route of administration for topical as well as systemic therapies because of their specific advantages.

The current adherence for chronic illnesses estimated by the WHO is to be on average only 50%, which is of growing concern to the pharmaceutical companies, especially given the global trends in healthcare reform. The electronic architecture of Gilbert’s inhaler is expected to allow for modulation of the dosage to compensate for previous deviations from the prescribed therapy and as such constitute a paradigm shift in patient medication adherence.


The market of pulmonary drug administration is projected to reach $ 52.4 billion by 2021, strongly increased from $ 36 billion in 2016. Asthma and COPD represent the largest market segment, 73%, of the inhaled drug market worldwide. The chart in the figure below illustrates the many market opportunities for new classes of inhaled drugs. The world market for asthma drugs was estimated to exceed $ 29 billion by 2019 with the US market accounting for approximately half of the global total.

Sales have grown steadily in the US and account for approximately 54% of global respiratory sales. In terms of revenue, asthma and COPD therapeutics area historically rank as the 6th largest single source of sales revenue for the pharmaceutical industry.

The rise in the incidences of asthma and COPD combined with the possibilities of delivering many other medications through inhalation create a significant market opportunity. In addition, as pipelines weaken and many blockbuster drugs are coming off patent, the pharmaceutical companies are scrambling for new sources of revenue. The respiratory disease market is becoming increasingly saturated for most drug classes, namely inhaled steroids and bronchodilators. This will provide huge opportunities for manufacturers to invest in the inhaler device market.

By developing the new Gilbert inhaler devices, Gilbert is taking advantage of this very significant market opportunity.

50% Asthma
15% COPD
9% Diabetes
8% Asthma/COPD
5% Narcotic Analgesics
4% Antibiotic
4% Cystic Fibrosis
1% Antiviral
1% Hormone Therapy
1% Influenza
1% Anaphylaxis
1% Multiple Sclerosis

Current market for inhaled pharmaceuticals

Our Partners

• TU Delft
• NHL University of Applied Sciences
• University Medical Center Utrecht
• Fluidda



Gilbert Technologies B.V.
High Tech Campus 27
5656 AE Eindhoven – NL

Gilbert Technologies 2020